Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397226 | 0.89 | GABRA5 (0.44) | GABRA5GABRA1RAB9AGPR119DRD2 | |
| SCHEMBL2393680 | 0.89 | GABRA5 (0.44) | GABRA5GABRA1RAB9AGPR119DRD2 | |
| SCHEMBL2398405 | 0.87 | GPR119 (0.42) | GABRA5IDH1RAB9AGPR119HPGDS | |
| SCHEMBL2394389 | 0.87 | GPR119 (0.42) | GABRA5IDH1RAB9AGPR119HPGDS | |
| SCHEMBL2394392 | 0.87 | GPR119 (0.42) | GABRA5IDH1RAB9AGPR119HPGDS | |
| SCHEMBL2396680 | 0.85 | GPR119 (0.35) | GABRA5RAB9AGPR119 | |
| SCHEMBL2394333 | 0.82 | GPR119 (0.44) | GABRA5IDH1RAB9AGPR119KCNH2 | |
| SCHEMBL4403130 | 0.80 | GABRA5 (0.48) | GABRA5GABRA1RAB9ACSNK2A2CSNK2A1 | |
| SCHEMBL13534650 | 0.77 | GABRA5 (0.40) | GABRA5GPR119DRD2DRD3CSNK2A2 | |
| SCHEMBL2395228 | 0.77 | GPR119 (0.42) | RAB9AGPR119HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| WO-2010004344-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GABRA5 195/4885GABRA1 175/4885IDH1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.